NEWS
Spoke at “RINKFESTIVAL 2025” hosted by Kanagawa Regenerative and Cellular Medicine Industrialization Network (RINK)
We have been invited to speak at SessionE: TOP Runners in the Regenerative Medicine Industry (18:30 -19:30) at “RINK FESTIVAL 2025” to be held on February 14, 2025 (Friday) from 13:00-21:00. For details, please refer to the following.https://rink.kanagawa.jp/archives/7289
Spoke at a seminar organized by Kyoto Sangyo 21 “Kyo-MED (Cross-Industrial Collaboration Team for Medical and Nursing Care)” on “Challenges of University-Launched Ventures: To Deliver ‘Teething Medicines’ to Patients as Early as Possible.
Spoke at a seminar hosted by Kyoto Sangyo 21 “Kyo-MED (Cross-Industry Collaboration Team for Medical and Nursing Care)” entitled “Challenges of University-Launched Ventures～Speaker at the seminar “Challenges of University-Launched Venture - To Deliver ‘Teething Drugs’ to Patients as Soon as Possible. PDF: https://www.ki21.jp/wordpress/wp-content/uploads/2025/01/KyoMED_chirashi_250116-2.pdf
Honoka Kiso, CEO of our company, spoke at an event hosted by LINK-J on Friday, January 17, 2025, at 12:00 p.m.
Mitsuru Miyata and Honoka Kiso spoke at “Miyaman's Venture Talk vol. 11,” an event hosted by the Life Science Innovation Network Japan (LINK-J), Mr. Miyata took the stage at the event. In addition to providing seasonal information on life science ventures, we discussed our business and future venture story with science writer Mitsuru Miyata at […]
Participated in “Startup Horizon 2024 -Countdown to Global Startup EXPO Event 2025-” as a speaker
Speaker at Startup Horizon 2024 -Countdown to Global Startup EXPO Event 2025-, organised by the Ministry of Economy, Trade and Industry, METI Kinki and JETRO (Japan External Trade Organisation).https://global-startup-expo.go.jp/startup-horizon2024/
The start date for the investigator-initiated clinical trial of a tooth regeneration treatment for congenital edentulism ( known as “teething medicine”) has been set.
Tazuke Kofukai FoundationThe research plan (approved by the Pharmaceuticals and Medical Devices Agency (PMDA) on 25 March 2024) for a tooth regeneration treatment for congenital edentulism ( known as “teething medicine”) being conducted by the Kitano Hospital and affiliated groups. The start date of the investigator-initiated clinical trial at Kyoto University Hospital has now been […]